Kornimate/medical-research-clean huggingface dataset:
the clinical benefit and risk of oral aspirin for unruptured intracranial aneurysm combined with cerebral ischemia

Conditions: Intracranial Aneurysm; Cerebral Ischemia

Summary: the first purpose of this study is to find out the clinical benefit and risk of oral aspirin for unruptured intracranial aneurysm (small than 7mm) combined with cerebral ischemia in patients in the real world. the second purpose of this study is to get the prediction model of aneurysm's rupture in patients who has unruptured intracranial aneurysm (small than 7mm) combined with cerebral ischemia , and find out who is suitable for oral aspirin.

the investigators try to collect the information of the patients have unruptured intracranial aneurysm combined with cerebral ischemia when oral aspirin.the characteristics of this study are large sample, multi center and prospective.in the real world, more and more patients are checked out unruptured intracranial aneurysm combined with cerebral ischemia.the investigators can collect the information such as how they use aspirin (dose, frequency, duration of treatment), demographic information, past history, daily life habits, morphological characteristics of the aneurysm, how they use other antithrombotic drugs.the investigators will record whether the aneurysm ruptured and have hemorrhage, ischemic stroke, death, changes in the morphology of aneurysm, mri permeability image index changes. finally the investigators will get the clinical benefits and risks of using aspirin and build the prediction model of rupture and hemorrhage for aneurysm, find out who is suitable for oral aspirin.

Eligibility criteria:
inclusion criteria: 1. has the diagnosis of unruptured intracranial aneurysm (using the cta/dsa,smaller than 7mm) 2. has the history of tia or any other diseases of cerebral ischemia 3. older than 18 years old 4. sign the informed consent exclusion criteria: 1. has the history of intracranial aneurysm rupture hemorrhage or has more than one aneurysm untreated 2. has a family history of intracranial aneurysm 3. has avm，mmd, intracranial tumor, hydrocephalus or intracranial hemorrhage 4. refuse to sign the informed consent 5. allergic to contrast medium

Keywords: intracranial aneurysm cerebral ischemia aspirin
cognitive assessment and brain function evaluation in patients with non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease; Cognitive Impairment

Summary: the purpose of this study is to explore the relationship between non-alcoholic fatty liver disease and cognitive impairment and evaluate the effect of metabolic surgery or lifestyle intervention on cognition.

previous research has shown that non-alcoholic fatty liver disease (nafld) is associated with an increased risk of cognitive impairment. even though there are many noninvasive tests available, a liver biopsy is still required for the accurate diagnosis of nafld. however, there are now few studies on cognitive function in patients with nafld based on pathological diagnosis. on one hand, in the cross-sectional study, biometric measurements, cognitive assessment, magnetic resonance imaging (mri) results are analysed to explore the differences among control subjects and nafld patients undergoing liver biopsy. one the other hand, in the longitudinal study, changes in cognitive scales and mri results in nafld patients both at baseline and 12-48 months after intervention are collected to investigate whether surgical intervention and weight control benefit brain function.

Eligibility criteria:
inclusion criteria: * \>6 years of education * right handed exclusion criteria: * consumed excessive alcohol (≥140 g/week for males or ≥ 70 g/week for females) * with history of other liver diseases including chronic hepatitis, biliary obstructive diseases or autoimmune hepatitis * with thyroid diseases * in a state of anxiety or depression * inability to complete cognitive function scales

Keywords: mri cognitive function
comparison of desensitizing materials

Conditions: Dentin Hypersensitivity

Summary: to compare the efficacy of two commercially available in-office desensitizing agents (fluoraphat pro and vivasens®), in the treatment of dentinal hypersensitivity.

dentine hypersensitivity (dh) is a condition that occurs in non-pathological, non-defective teeth and is defined as "a short, sharp pain in response to stimuli, typically thermal, evaporative, tactile, osmotic or chemical and which cannot be attributed to any other dental defect or pathology". the incidence of dh ranges from 4% to 74% in several studies. mandibular first molars, canines and premolars of both jaws are most commonly affected by dh. the pathogenesis of dh is linked to exposure of dentinal tubules that can occur in the oral cavity due to dental erosion from acidogenic diets, aggressive tooth-brushing, injudicious use of whitening products, gingival recession, periodontal debridement or surgery. the most commonly reported initiating factor is cold drinks. management usually involves methods that can achieve one or both of the following objectives; i) alteration of fluid flow in the dentinal tubules and ii) modification or blocking of the pulpal nerve response. a broad range of products that achieve these objectives have been developed after rigorous trials and can be used in-office or at home depending on the severity of the condition. these products are commonly referred to as desensitizing agents. grossman suggested that an ideal desensitizing agent should be non-irritating to the pulp, relatively painless on application, easy to apply, rapid in action, effective for long periods of time and should not stain the teeth. the use of dentine desensitizers has become one of the most common methods in managing dh. the most commonly used desensitizers contain components such as fluoride, triclosan, benzalkonium chloride, ethylene diaminetetraacetic acid and glutaraldehyde. fluoraphat pro (neumunster, germany) and vivasens® (ivoclar vivadent, schaan, liechtenstein, switzerland) are two agents that have been tested for use as dentine desensitizers and are currently available for commercial use. in the present study, two such varnishes vivasens (ivoclar vivadent, schaan, liechtenstein, and switzerland) and fluoraphat (promedical neumunster, germany) have been used. the present study aims to establish which of the two desensitizing agents has better efficacy in reducing hypersensitivity in patients who have been previously diagnosed with dh.

Eligibility criteria:
inclusion criteria: * males and females aged between 18 and 50 years * patient should have at least 2 teeth with dentinal hypersensitivity * sound tooth structure * willingness to participate in the study exclusion criteria: * gingival recession * caries * non-carious lesions (attrition, abrasion, erosion, abfraction) * teeth restored with dental filling * fractured or cracked tooth * microleakage
acupressure for covid-19 related quality of life and stress

Conditions: Quality of Life; Stress

Summary: this study is being conducted to evaluate the efficacy of acupressure in promoting health and well-being among healthcare workers during the covid-19 pandemic. the investigators hypothesize that providing participants with a remote and standardized self-acupressure training program will improve hrqol and the perception of stress. in the event that the study demonstrates acupressure to be safe and effective for this indication, the training could be scaled up and deployed at low-cost nationally and internationally.


Eligibility criteria:
inclusion criteria: * all adult patients (18 years of age and over) who are health care providers according to self-report will be eligible for participation with the exception of subjects meeting exclusion criteria as below. exclusion criteria: * exclusion criteria includes subjects who are physically unable to participate (e.g., from severe arthritis) or cognitively unable to participate (e.g., from dementia) will be excluded. patients unable to provide their own informed consent will be excluded. patients under the age of 18 years will be excluded. pregnant women will be excluded. patients who have previous training in acupressure will be excluded.
standard triple therapy vs sequential therapy in treatment of h pylori infection

Conditions: Helicobacter Infection

Summary: traditionally, h pylori infection has been treated with conventional triple therapy. this includes amoxicillin, clarithromycin and a proton pump inhibitor all given daily for 10-14 days. in europe, the guidelines now advocate treatment of h pylori with sequential therapy which is 5 days of amoxicillin therapy with proton pump inhibitor followed by 5 days of clarithromycin, metronidazole, and proton pump inhibitor with better response rates. we hypothesize that h. pylori resistance pattern and treatment response rates observed in europe will not be predictive of resistance patterns and response rates in the united states.


Eligibility criteria:
inclusion criteria: subject has signed informed consent subject is an adult older than 18 yrs old and requires an upper endoscopic evaluation if female and of child bearing potential, subject has a negative pregnancy test and is not nursing. patient has not received prior treatment for h pylori subject is able to understand and comply with study procedures exclusion criteria: recent use (within 4 weeks) of any of the medications used in the treatment of h pylori(amoxicillin, clarithromycin, metronidazole) subject undergoing endoscopy for acute gastrointestinal bleeding subject has an allergy to any of the medications used in the treatment of h pylori subject has a history of esophageal or gastric carcinoma including lymphoma subject has esophageal varices or undergoing endoscopy for esophageal banding subject is taking warfarin or clopidogrel subject has coagulopathy that precludes safe biopsy of the biopsy areas subject has comorbidity that precludes safe participation in the study subject is a pregnant female subject has a history of h. pylori infection. patient is already enrolled in gi study. history of ugi surgery other than nissen fundoplication
observational prospective study of the predicted value of immature thrombocytes counts in three different groups of critically ill patients

Conditions: Critically Ill Patients; Neutropenic Fever Patients; Patients With Hip Fractures

Summary: immature platelet fraction (ipf) is a new value in cbc blood tests recent studies showed that this value may be another prognostic factor in critically ill patients such as those admitted to icu, or those with neutropenic fever. the purpose of the study is to check if the ipf may be used as a prognostic factor in these patients

in this study we have 3 groups of patients * patients admitted to icu * patients admitted with neutropenic fever * patients admitted with hip fractures it is a prospective study, not interventional, we'll take blood samples of these patients including cbc count eith ipf and other inflammation markers such as crp and we'll compare crp to ipf in addition to clinical follow-up of the patient till discharge. at the end of this study we'll compare the efficacy of ipf as a prognostic factor in these patients

Eligibility criteria:
inclusion criteria: - admission to hospital blood sample is taken between 24:00 pm till 15:00 pm exclusion criteria: * blood sample is taken after 15:00 pm in the first day of admission during the week * blood sample is taken on weekend: thursday 15:00 pm till saturday 24:00 pm

Keywords: ipf immature platelet fraction icu neutropenic fever hip fracture critically ill
the role of muscular ultrasound in predicting weaning success

Conditions: Respiratory Insufficiency

Summary: when attempting to wean a patient from the ventilator, even if he/she passes the spontaneous breathing test, 10-20% of the time extubation failure occurs and the patient is reintubated. when the patient is reintubated the mortality rate increases and the length of intensive care unit stay is also increased. it is vital to intensively assess the patient before extubation and correctly predict extubation success. muscular ultrasound may be helpful in these situations.


Eligibility criteria:
inclusion criteria: * adult patients undergoing weaning from mechanical ventilation * patients who have been mechanically ventilated for more than 72 hrs exclusion criteria: * pregnant patients * patients with previous neuromuscular diseases * difficulties in muscular ultrasound (dressing, operation, etc)

Keywords: ultrasonography weaning
effect of spironolactone in the prevention of anthracycline-induced cardiotoxicity (spirotox)

Conditions: Cardiotoxicity; Neoplasms; Chemotherapy Effect; Heart Failure

Summary: the goal of this clinical trial is to evaluate the effect of spironolactone in the primary prevention of cardiotoxicity in cancer patients who are undergoing chemotherapy with anthracycline within 12 months. the main question it aims to answer is: • does spironolactone reduce the incidence of cardiotoxicity in patients undergoing anthracycline chemotherapy? participants will: * be cancer patients over 18 years starting treatment with anthracycline; * be randomized to receive either spironolactone or a placebo for 1 year; * undergo assessments of their left ventricular ejection fraction (lvef), global longitudinal strain, and cardiac biomarkers over the 12-month period. researchers will compare the spironolactone group to the placebo group to see if cardiotoxicity incidence differs between the two.

objective: to assess the potential of spironolactone in preventing anthracycline-induced cardiotoxicity among cancer patients. background: there's ongoing debate and a dearth of evidence regarding the role of mineralocorticoid receptor antagonists, such as spironolactone, in averting anthracycline-induced cardiotoxicity. study design: a randomized, double-blind, placebo-controlled trial conducted at a single center. sample size: 264 patients. intervention: eligible participants will be randomized on a 1:1 basis to either receive spironolactone or a placebo over a 12-month period. primary outcome: incidence of cardiotoxicity at the 12-month mark.

Eligibility criteria:
inclusion criteria: * patients diagnosed with cancer indicated for anthracycline chemotherapy treatment * age 18 and above * signed informed consent form exclusion criteria: * previous use of anthracycline. * hypersensitivity to any mineralocorticoid receptor antagonists * symptoms of heart failure (exertional dyspnea, orthopnea, nocturnal paroxysmal dyspnea, and pulmonary or systemic congestion) * left ventricular ejection fraction (lvef) \< 45% * previous diagnosis of cardiomyopathy, coronary artery disease, or moderate to severe mitral or aortic disease * renal insufficiency defined as an estimated glomerular filtration rate \< 30 ml/min/m2 * hyperkalemia, defined as serum potassium ≥ 5.0 mmol/l * chronic liver disease, defined aspartate aminotransferase (ast) or alanine aminotransferase (alt) values more than 3 times the upper limit of normal * current participation in another study

Keywords: cardiotoxicity anthracyclines spironolactone
safety and tolerability of ma09-hrpe cells in patients with stargardt's macular dystrophy(smd)

Conditions: Stargardt's Macular Dystrophy

Summary: the purpose of this study is to evaluate the safety and tolerability of rpe cellular therapy in patients with smd

* to evaluate the safety and tolerability of rpe cellular therapy in patients with smd * to evaluate the preliminary efficacy of ma09-hpre in patients with smd

Eligibility criteria:
inclusion criteria: * adult male or female over 20 years of age. * clinical diagnosis of advanced smd. * the visual acuity of the eye to receive the transplant will be no better than hand movement. * the visual acuity of the eye that is not to receive the transplant will be no better than 24 (20/320) early treatment of diabetic retinopathy study (etdrs) letters. exclusion criteria: * history of malignancy. * history of myocardial infarction in previous 12 months. * history of diabetes mellitus. * any immunodeficiency. * any current immunosuppressive therapy other than intermittent or low dose cortico steroids. * serologic evidence of infection with hepatitis b, hepatitis c, or hiv. * current participation in any other clinical trial. * participation within previous 6 months in any clinical trial of a drug by ocular or systemic administration. * any other sight-threatening ocular disease. * any chronic ocular medications. any history of retinal vascular disease (compromised blood-retinal barrier). glaucoma. uveitis or other intraocular inflammatory disease. significant lens opacities or other media opacity. ocular lens removal within previous 3 months
evaluation of the analgesic effect of music therapy in critically ill patients during potentially painful nursing procedures: a pilot study

Conditions: Pain

Summary: pain is a common problem encountered in about 60 % of critically ill patients who can communicate. its occurrence can be related to several causes, mainly dominated by invasive procedures. pain management is typically based on a combination of prevention, evaluation, and therapeutic agents. however, it appears important to develop adjuvant approaches. music therapy is one of them and that has been evaluated in various medical conditions. the aim of our study is to evaluate the analgesic effect of music therapy in critically ill patients during potentially painful nursing procedures.


Eligibility criteria:
inclusion criteria: * all adult patients (age≥18 years) hospitalized in intensive care unit * requiring mechanical ventilation * who cannot communicate * with a richmond agitation sedation scale (rass) score \[-3; +4\] exclusion criteria: * age \< 18 years * receiving neuromuscular blockade

Keywords: critically ill mechanical ventilation pain nursing music
neuromuscular deficits in jump-landing technique in young basketball

Conditions: Sport Injury; Motor Skills Disorders; Biomechanical Lesions

Summary: basketball is a team sport that requires specific motor skills to develop different technical-tactical actions. within the specific movements, landings after a jump are very common and require optimal technical performance, good stability and symmetry. alterations in these components have been linked to an increased risk of injury. the objective of the present study is to identify functional alterations in the jump / landing technique that basketball players present. cross-sectional study carried out from septembre to juny. the participants were basketball players aged 12 to 14 years. the main variables were: ankle stability, dynamic knee valgus, central stability, symmetry of the lower extremities. the tests used were: abalakov test, single hop test for distance, single-leg vertical countermovement jump test, cross over hop test, one leg balance test.

basketball is a team sport that requires specific motor skills to develop different technical-tactical actions. within the specific movements, landings after a jump are very common and require optimal technical performance, good stability and symmetry. alterations in these components have been linked to an increased risk of injury. the objective of the present study is to identify functional alterations in the jump / landing technique that basketball players present. a cross-sectional study carried out from septembre to juny. the participants were basketball players aged 12 to 14 years. the main variables were: ankle stability, dynamic knee valgus, central stability, symmetry of the lower extremities. the tests used were: abalakov test, single hop test for distance, single-leg vertical countermovement jump test, cross over hop test, one leg balance test.

Eligibility criteria:
inclusion criteria: * age from 12 years to 14 years at testing (both included). * to be actively competing during the study. * voluntarily sign the informed consent form. * not meet the exclusion criteria. exclusion criteria: * presented any injury (overuse or acute) at the time of testing. * psychological or psychiatric diseases diagnosed. * oncological diseases diagnosed. * did not attend on the day of the assessment.

Keywords: basketball physical therapy youth athletes movement
suture of uterus and ultrasound repair evaluation

Conditions: Uterine Scar Defect

Summary: this study compares three techniques of uterine closure on myometrium thickness evaluated by ultrasound six months after the primary cesarean. the three techniques include: 1) locked single layer closure; 2) double layer closure with a first continuous locked suture and a second imbricating continuous suture; 3) double layer closure with a first continuous unlocked suture of the deep portion of the myometrium avoiding the inclusion of the decidua and a second unlocked continuous suture that approximate the upper portion of the myometrium. the primary outcome is the mean myometrium thickness at the site of the uterine scar evaluated by transvaginal ultrasound at six months after cesarean.


Eligibility criteria:
inclusion criteria: * planned cesarean * primary cesarean * ≥ 38 gestational weeks exclusion criteria: * previous cesarean * women \< 18 years old * multiple gestation * mullerian anomalies * active labor * diabetes * bmi \>35 kg/m2 * placenta praevia * chronic systemic disease

Keywords: cesarean ultrasound hysterotomy uterus suture
radiofrequency probe for management of unresectable bile duct and pancreatic cancer

Conditions: Pancreatic Cancer

Summary: the purpose of this study is to determine whether the use of an fda approved endoscopic bipolar catheter (endohpb) will ablate tissue in malignant tumors within the pancreatic ducts.

only a small proportion of patients with biliary obstruction caused by cholangiocarcinoma or pancreatic cancer are suitable for surgical resection. therefore most patients with malignant biliary obstruction will need palliation of their jaundice to relieve the symptoms of pruritus, malabsorption, sepsis and to minimize potential hepatorenal complications. restoring biliary flow with relief of jaundice is the primary goal in the palliation of obstructive biliary malignancy. drainage at endoscopic retrograde cholangiopancreatography (ecrp) is established as a safer approach than at percutaneous transhepatic cholangiography (ptc) because it has a lower risk of bile leak, infection and hemorrhage. ecrp is the first approach to relieve malignant biliary obstruction but sometimes it is not technically possible to stent the patient by this approach, then a ptc needs to be undertaken. self expanding mesh metal stents (sems) were introduced back in the 1990s. problems can still arise with the use of covered stents such as cholecystitis, pancreatitis or tumor overgrowth at the end of the stent, and not all studies have shown that covered stents actually reduce the problems of tumor ingrowth and consequent stent occlusion. endohpb can be deployed via an ercp or ptc route. by using radiofrequency (rf) energy to heat the tissue in the duct prior to insertion of the stent, the surrounding tissue becomes coagulated and this may may delay tumor growth and the time before the stent lumen becomes blocked. thereby this allows increased periods between the need for intervention and further stent deployment. if endohpb use of luminal rf is demonstrated to be effective in luminal tumor ablation, it may have an additional role as a form of neoadjuvant therapy in cholangiocarcinoma and pancreatic cancer.

Eligibility criteria:
inclusion criteria: * either gender greater than or equal to 18 years of age. * pancreatic cancer or cholangiocarcinoma unsuitable for surgical resection. criteria of unresectability being based on 1) metastatic disease or 2) locally advanced disease. * biliary obstruction * subjects capable of giving informed consent * life expectancy of at least 3 months exclusion criteria: * cardiac pacemaker * patient unstable for endoscopy * inability to give informed consent * uncorrected coagulopathy * pregnancy * karnofsky score less than 40%

Keywords: endohpb